Literature DB >> 18312935

Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma.

Ismail T Koksal1, Ahter D Sanlioglu, Bahri Karacay, Thomas S Griffith, Salih Sanlioglu.   

Abstract

OBJECTIVE: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) has recently been investigated because of its ability to selectively kill cancer cells. Despite recent publications mainly focusing on TRAIL resistance in cancer cells, little is known about how TRAIL contributes to the carcinogenesis process. Because the expression patterns of TRAIL and its receptors in patients with prostate carcinoma have recently been reported, this study investigated the significance of TRAIL and TRAIL receptor expression in connection to serum prostate-specific antigen (PSA) and Gleason scoring.
MATERIALS AND METHODS: A total of 98 patients were included in the study. Gleason scores, PSA, TRAIL, and TRAIL receptor expressions were used for the comparison purposes. The Spearman rho correlation test was administered to reveal the correlations among the variants. The Kruskal Wallis-Mann Whitney U or Friedman-Wilcoxon signed ranks test determined the statistical significance between the pairs. Multinomial and/or multiple binary logistic regression analyses were deployed to test whether TRAIL markers were independent variables to predict the prognosis of prostate cancer. Kaplan-Meier and log-rank tests were used to determine the survival rates.
RESULTS: High-serum PSA levels were correlated with higher levels of TRAIL and TRAIL receptor expressions. Patients with high Gleason scores had higher levels of TRAIL-R4 decoy receptor expression but lower levels of TRAIL death ligand expression.
CONCLUSIONS: TRAIL-R4 decoy receptor expression is strongly correlated with PSA recurrence, which is suggestive of poor prognosis. High levels of TRAIL-R4 expression but low levels of TRAIL death ligand expression are connected to decreased survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18312935     DOI: 10.1016/j.urolonc.2007.01.022

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  16 in total

1.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 2.  TRAIL-mediated signaling in prostate, bladder and renal cancer.

Authors:  Christina Voelkel-Johnson
Journal:  Nat Rev Urol       Date:  2011-06-14       Impact factor: 14.432

3.  Role of TNF-related apoptosis-inducing ligand (TRAIL) in the pathogenesis of varicocele-induced testicular dysfunction.

Authors:  Orcun Celik; Omer Kutlu; Merih Tekcan; Ciler Celik-Ozenci; Ismail T Koksal
Journal:  Asian J Androl       Date:  2012-12-31       Impact factor: 3.285

4.  Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.

Authors:  L O'Leary; A M van der Sloot; C R Reis; S Deegan; A E Ryan; S P S Dhami; L S Murillo; R H Cool; P Correa de Sampaio; K Thompson; G Murphy; W J Quax; L Serrano; A Samali; E Szegezdi
Journal:  Oncogene       Date:  2015-06-08       Impact factor: 9.867

5.  TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.

Authors:  Atil Bisgin; Ender Terzioglu; Cigdem Aydin; Burcak Yoldas; Veli Yazisiz; Nilufer Balci; Huseyin Bagci; Reginald M Gorczynski; Cezmi A Akdis; Salih Sanlioglu
Journal:  BMC Musculoskelet Disord       Date:  2010-08-27       Impact factor: 2.362

6.  Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis.

Authors:  Omer Kutlu; Erdem Akkaya; Ismail Turker Koksal; Ibrahim Cumhur Bassorgun; Mehmet Akif Ciftcioglu; Salih Sanlioglu; Erdal Kukul
Journal:  Int Urol Nephrol       Date:  2009-08-25       Impact factor: 2.370

7.  A Study of the Impact of Death Receptor 4 (DR4) Gene Polymorphisms in Alzheimer's Disease.

Authors:  Tuba Gökdoğan Edgünlü; Aynur Ozge; Osman Özgür Yalın; Seval Kul; Mehmet Emin Erdal
Journal:  Balkan Med J       Date:  2013-09-01       Impact factor: 2.021

Review 8.  Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.

Authors:  Ufuk Mert; Ahter Dilsad Sanlioglu
Journal:  Cell Mol Life Sci       Date:  2016-08-10       Impact factor: 9.261

9.  Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.

Authors:  Atil Bisgin; Aysegul Kargi; Arzu D Yalcin; Cigdem Aydin; Deniz Ekinci; Burhan Savas; Salih Sanlioglu
Journal:  BMC Cancer       Date:  2012-02-07       Impact factor: 4.430

10.  Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.

Authors:  Leszek Gottwald; Janusz Piekarski; Robert Kubiak; Jarosław Szwalski; Grażyna Pasz-Walczak; Piotr Sęk; Michał Spych; Jacek Suzin; Wiesław Tyliński; Arkadiusz Jeziorski
Journal:  Arch Gynecol Obstet       Date:  2013-04-13       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.